New Treatments for Atopic Dermatitis to Come
Stephan Weidinger discusses the data on an OX40 ligand inhibitor that aims to target immune activation in atopic dermatitis (AD), which plays a crucial role in the proliferation and survival of antigen-specific T-cells. He also mentions other drugs in development, including one targeting OX40 receptors, IL-2 for stimulating T regulatory cells, and long-term safety and efficacy data for established biologics.
